Clinical Features of Vitiligo and Social Impact on Quality of Life

Seneschal Julien

doi:10.5826/dpc.1304S2a312S

Clinical Features of Vitiligo and Social Impact on Quality of Life

Authors

Seneschal Julien Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin disorders, Hôpital Saint-André; University of Bordeaux, CNRS, Immuno ConcEpT, UMR 5164, Bordeaux, France

Keywords:

vitiligo, quality of life, social impact, mental health

Abstract

Vitiligo is the most common cause of depigmentation and its estimated worldwide prevalence ranges from 0.5% to 2%. The disease is characterized by the development of white macules resulting from a loss of epidermal melanocytes. The term vitiligo (nonsegmental) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. The skin plays an important role in our interaction with the world and any change in the skin colour can have important psychological consequences. In this line, vitiligo has a major impact on quality of life.
In this review, we will detail the most recent data on the clinical features of vitiligo and its impact on quality of life.

References

Ezzedine K, Eleftheriadou V, Whitton M, Geel N van. Vitiligo. Lancet 2015;386:74–84.

Picardo M, Dell’Anna ML, Ezzedine K, et al. Vitiligo. Nature Reviews Disease Primers 2015;1:15011.

Taieb A, seneschal julien, Mazereeuw-Hautier J. Special Considerations in Children with Vitiligo. Dermatologic clinics 2017;35:229–33.

Silverberg NB. Recent advances in childhood vitiligo. Clin Dermatol 2014;32:524–30.

Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol 2021;22:757–74.

Geel N van, Speeckaert R, Taieb A, et al. Koebner’s phenomenon in vitiligo: European position paper. Pigment Cell & Melanoma Research 2011;24:564–73.

Kumar S, Vinay K, Choudhary R, et al. Clinicodemographic features of mixed vitiligo: a case–control study. Int J Dermatol 2022;61:982–7.

Ezzedine K, Diallo A, Léauté-Labrèze C, et al. Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo. The British journal of dermatology 2012;166:539–44doi:10.1111/j.1365-2133.2011.10709.x.

Ezzedine K, Thuaut AL, Jouary T, Ballanger F, Taieb A, Bastuji‐Garin S. Latent class analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes. Pigment Cell Melanoma Res 2014;27:134–9.

Geel N van, Speeckaert R. Segmental Vitiligo. Dermatol Clin 2017;35:145–50.

Oh J, Lee RW, Lee HR, et al. Classification of facial and truncal segmental vitiligo and its clinical courses including recurrence rate and patterns: a retrospective review of 956 patients. Br J Dermatol 2021;184:750–3.

Geel N van, Grine L, Wispelaere PD, Mertens D, Prinsen CAC, Speeckaert R. Clinical visible signs of disease activity in vitiligo: a systematic review and meta‐analysis. J Eur Acad Dermatol Venereol 2019;33:1667–75doi:10.1111/jdv.15604.

Sosa JJ, Currimbhoy SD, Ukoha U, et al. Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo. J Am Acad Dermatol 2015;73:272–5.

Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J. The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes. J Eur Acad Dermatol Venereol 2022;36:1507–23.

Salzes C, Abadie S, seneschal julien, et al. The Vitiligo Impact Patient Scale (VIPs): Development and Validation of a Vitiligo Burden Assessment Tool. Journal of Investigative Dermatology 2016;136:52–8.

Porter J, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders A study of patients with vitiligo. Gen Hosp Psychiatry 1979;1:73–7.

Talsania N, Lamb B, Bewley A. Vitiligo is more than skin deep: a survey of members of the Vitiligo Society. Clin Exp Dermatol 2010;35:736–9.

Nogueira LSC, Zancanaro PCQ, Azambuja RD. Vitiligo e emoções. An Bras Dermatol 2009;84:41–5.

Schmid‐Ott G, Künsebeck H, Jecht E, et al. Stigmatization experience, coping and sense of coherence in vitiligo patients. J Eur Acad Dermatol Venereol 2007;21:456–61.

Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Heal Qual Life Outcomes 2003;1:58.

Krüger C, Schallreuter KU. Cumulative Life Course Impairment in Vitiligo. Curr Probl Dermatol 2013;44:102–17.

Silverberg JI, Silverberg NB. Quality of Life Impairment in Children and Adolescents with Vitiligo. Pediatr Dermatol 2014;31:309–18.

Homan MWL, Korte JD, Grootenhuis MA, Bos JD, Sprangers MAG, Veen JPWVD. Impact of childhood vitiligo on adult life. Br J Dermatol 2008;159:915–20.

Brown MM, Chamlin SL, Smidt AC. Quality of Life in Pediatric Dermatology. Dermatol Clin 2013;31:211–21.

Manzoni APD da S, Weber MB, Nagatomi AR da S, Pereira RL, Townsend RZ, Cestari TF. Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders*. An Bras Dermatol 2013;88:894–9.